Stockscreener 앱 받기
5.09%
전일 마감가:
$8.05
열려 있는:
$8.06
하루 거래량:
1.17M
Relative Volume:
0.45
시가총액:
$585.35M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-5.1879
EPS:
-1.63
순현금흐름:
$-71.49M
1주 성능:
+0.06%
1개월 성능:
+22.61%
6개월 성능:
+9.87%
1년 성능:
+233.07%
1일 변동 폭
$7.91
$8.52
1주일 범위
$6.945
$8.54
52주 변동 폭
$2.4821
$14.84
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
ALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ALT | 8.455 | 585.35M | 409.00K | -101.35M | -71.49M | -1.63 |
| VRTX | 448.10 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.93 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.76 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.01 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.66 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat
(ALT) Trading Report - Stock Traders Daily
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times
Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results | ALT Stock News - StockTitan
What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com
B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha
Altimmune Unusual Options Activity For November 13 - Benzinga
Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha
Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks
Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey
UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq
GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India
Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments - GuruFocus.com
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... - Yahoo Finance
Altimmune (ALT) Stock Soars 27%: Phase 2 Data On Obesity Drug Ignites Market Optimism - Barchart
Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline - TipRanks
Altimmune Stock Rallies 30% on Updates - citybiz
Altimmune stock rallies 30% on business updates, UBS buy rating - MSN
Altimmune stock rallies 30% on business updates, UBS buy rating (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Traders Purchase Large Volume of Altimmune Call Options (NASDAQ:ALT) - MarketBeat
Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000 - GuruFocus.com
Altimmune Appoints Gregory Weaver as CFO for Growth - TipRanks
UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT) - MarketBeat
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Altimmune Stock Goes Parabolic Following Q3 Results As CEO Touts 2025 As ‘Transformational Year:’ Retail Upbeat - MSN
Altimmune Appoints Greg Weaver as CFO - citybiz
Altimmune Appoints Chief Financial Officer - Contract Pharma
Altimmune says ‘something raised attention of FDA’ - TipRanks
Altimmune appoints Greg Weaver as CFO - TipRanks
Altimmune Names Greg Weaver Chief Financial Officer - MarketWatch
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - The Manila Times
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer - Marketscreener.com
How Altimmune Could Grab a Big Chunk of the GLP-1 Market - MarketBeat
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
Institutional investors control 59% of Altimmune, Inc. (NASDAQ:ALT) and were rewarded last week after stock increased 11% - Simply Wall St
Altimmune advances obesity treatment into Phase 3 trials By Investing.com - Investing.com South Africa
Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide - Seeking Alpha
Altimmune advances obesity treatment into Phase 3 trials - Investing.com India
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - The Manila Times
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알티뮨 주식 (ALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Drutz David | Director |
Aug 19 '24 |
Sale |
6.90 |
16,011 |
110,547 |
41,958 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
44,990 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
39,016 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
55,965 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
49,991 |
| Garg Vipin K | President and CEO |
Feb 02 '24 |
Option Exercise |
0.00 |
18,950 |
0 |
300,404 |
| Garg Vipin K | President and CEO |
Feb 01 '24 |
Option Exercise |
0.00 |
16,545 |
0 |
288,767 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
29,699 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
43,277 |
| Garg Vipin K | President and CEO |
Jan 30 '24 |
Option Exercise |
0.00 |
26,775 |
0 |
276,030 |
0.42%
0.16%
자본화:
|
볼륨(24시간):